Here at Affygility Solutions we often get asked, “When do I need an occupational exposure band (OEB) or occupational hazard categorization (OHC) report vs. an occupational exposure limit (OEL) monograph?” Well, let me explain.
Occupational exposure band reports are intended for early stage compounds with limited or no human data. The objective of an OEB report is to assign an early stage compound to a control band, without providing a specific numerical occupational exposure limit (OEL) or numerical acceptable daily exposure (ADE) (aka permitted daily exposure (PDE) value). And while the expert occupational toxicologist may perform some “back of the envelope” calculations to determine the appropriate control band assignment, it is unwise to present these calculations in the OEB report since the numbers will significantly change as the compound moves through development. In addition, the expert occupational toxicologist authoring the OEB report may also employ a “read-across” or professional judgement approach to similar compounds based on the compound of interest’s specific molecular structure.
In general, the control band assignment in an OEB report tends to be conservative and is more focused on what controls are necessary to protect employees and prevent cross-product contamination. At this stage of development there is still significant uncertainty in determining a specific numerical value for the OEL and ADE. OEB reports are of value because the frequency of exposure is non-routine, the batch sizes are small, the number of employees potentially exposed is limited, and the turnaround is rapid. With regards to calculating an ADE (or PDE) for compounds at this stage, as recommended in ISPE’s Risk-MaPP document (2nd Edition, p 39), an estimated ADE can be determined by taking the bottom of the control band, in µg/m3, and multiplying by a factor of 10 to estimate the ADE. At Affygility Solutions we use a factor of 5 (based on ECHA’s factor for human variability) since that would result in a more conservative ADE.
The advantages of an OEB report include:
The disadvantages of an OEB report include:
Now on the other hand, as a compound moves through drug development, and either has completed or nearing completion of Phase 2b clinical trials, a fully documented occupational exposure limit/acceptable daily exposure (aka. Permitted Daily Exposure) monograph should be developed. At this stage of development, there will be adequate human data (including pharmacokinetics data, longer-term studies, larger population studies, reproductive toxicology studies, etc.) to perform a specific determination of the OEL and ADE.
The advantages of an OEL/ADE monograph include:
The disadvantages of an OEL/ADE monograph include:
The use of OEB and OEL/ADE reports each have their own place and purpose. It is important that the end users, such as contract development and manufacturing organizations (CDMOs), understand what is required at each stage of drug development. If an organization wants more accurate numbers for an OEL or ADE, the only solution is to provide more accurate and complete data.
If you have any questions or need additional information, please contact us at Affygility Solutions.